NEW YORK (GenomeWeb) – Emory University's School of Medicine and global testing firm Eurofins Scientific today announced they have entered into an agreement whereby Eurofins will acquire a controlling interest in the Emory Genetics Laboratory (EGL).
EGL is a part of the Department of Human Genetics and provides testing services for hospitals and other institutional clients. It specializes in next-generation sequencing testing, especially for rare genetic disorders, the university said in a statement.
The lab will be renamed EGL Genetic Diagnostics. Financial and other details of the deal were not disclosed.
"This acquisition of EGL strengthens Eurofins' growing footprint in the specialty clinical diagnostics market," Eurofins CEO Gilles Martin said in a statement. "EGL provides Eurofins a leading position in the most technologically driven segment of the specialty clinical diagnostic testing market."
Earlier this month, Eurofins acquired Huntsville, Alabama-based genomics testing services provider Diatherix.